Patients on a combined antiretroviral therapy after maraviroc clinical test show no immunovirological impairment

► Maraviroc clinical test (MCT) as a method to select candidate patients to be treated with CCR5-antagonists. ► Advantages of MCT compared with other tropism assays. ► Long-term outcome of patients starting cART after MCT shows immunovirological efficacy. ► Tropism analysis during MCT shows no clinically relevant tropism change after short-term maraviroc monotherapy. The maraviroc clinical test (MCT) is a clinical approach to establish the indication of maraviroc treatment. In this study, we analysed the long-term outcome of patients receiving a combined antiretroviral therapy (cART) selected according to MCT results. Ninety-two consecutive HIV-infected patients underwent MCT. A virological response (